The epidemiology of Naganishia albida is the study of the distribution and determinants of this yeast-like fungus in different populations and environments. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some facts about the epidemiology of N. albida:
Based on phylogenetic analysis, N. albida was formerly known as Cryptococcus albidus but was reclassified in 2015.
N. albida is usually found on natural substrates, such as soil and plants, and rarely causes human infections. However, some cases of infection have been reported from various countries, such as Japan, Portugal, Iran, India, Brazil, and the USA.
The most common risk factor for N. albida infection is impaired cellular immunity, such as in patients with HIV, leukemia, or lymphoma. Other risk factors may include diabetes mellitus, chronic renal failure, organ transplantation, corticosteroid therapy, and trauma.
The clinical manifestations of N. albida infection differ based on the location and severity of the infection. Some examples are keratitis, pneumonia, encephalitis, cutaneous cryptococcosis, and disseminated cryptococcosis.
The treatment of N. albida infection depends on the severity and location of the infection. Antifungal drugs are the mainstay of therapy, but their efficacy may vary depending on the strain and the patient’s immune status. Some antifungal drugs that have been used to treat N. albida infection are amphotericin B, itraconazole, naftifine, fluconazole, and voriconazole. The course of treatment could last anything from a few weeks to several months. In some cases, surgical intervention may be required to remove infected tissue or drain abscesses.
Classification and Structure
Kingdom: Fungi
Division: Basidiomycota
Class: Tremellomycetes
Order: Filobasidiales
Family: Filobasidiaceae
Genus: Naganishia
Species:N. albida
The structure of Naganishia albida can be described in five points as follows:
Naganishia albida is a yeast-like fungus that belongs to the family Filobasidiaceae. It is currently only known for its yeast state.
Naganishia albida produces cream to pale pink colonies on culture media, primarily smooth and mucoid but sometimes rough and wrinkled.
Naganishia albida has globose to ovoid budding yeast-like cells, which measure 3.5-8.8 x 5.5-10.2 μm in size.
Naganishia albida has a polysaccharide capsule surrounding the cell wall and can be seen with India ink staining12. The capsule has four antigenic types: A1, A2, B1, and B2.
Naganishia albida does not form pseudohyphae or true hyphae; its sexual reproduction is unknown. It can assimilate various carbon and nitrogen sources and produce urease.
Antigenic Types
Different strains of N. albida can be distinguished by various criteria, such as phenol oxidase activity, capsular polysaccharide production, and DNA sequence analysis. Some of the strains that have been isolated and identified are:
N. albida var. albidus: This strain type of N. albida was initially isolated from the air in Japan. It is phenol oxidase-negative and capsular polysaccharide-positive.
N. albida var. kuetzingii: This strain was isolated from a grasshopper in Portugal. It is phenol oxidase-positive and capsular polysaccharide-negative.
N. albida var. ovalis: This strain was isolated from a tubercular lung. It is phenol oxidase-negative and capsular polysaccharide-negative.
N. albida FJI-L2-BK-P3: This strain was isolated from a dry moss in Portugal5. DNA sequence analysis shows it belongs to a different clade than the other strains.
Pathogenesis
The pathogenesis of Naganishia albida is the process by which this yeast-like fungus causes disease in humans or animals. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some aspects of the pathogenesis of N. albida:
N. albida is usually found on natural substrates, such as soil and plants, and rarely causes human infections.
Inhaling airborne particles is the most typical method of infecting spores or cells of N. albida, which can reach the lungs and cause pneumonia. Other routes of infection may include direct injection of the fungus into the skin, eyes, or other mucous membranes or ingesting contaminated food or water.
The most common risk factor for N. albida infection is impaired cellular immunity, such as in patients with HIV, leukemia, or lymphoma. Other risk factors may include diabetes mellitus, chronic renal failure, organ transplantation, corticosteroid therapy, and trauma.
N. albida has several virulence factors that enable it to evade the host immune system and cause tissue damage.
Host Defenses
The host defenses of Naganishia albida are the mechanisms by which the human or animal immune system protects itself from this yeast-like fungus. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some aspects of the host defenses of N. albida:
The innate immune system is the first defense against N. albida. It consists of physical barriers, such as the skin and mucous membranes, and cellular and molecular components, such as macrophages, neutrophils, natural killer cells, complement, and cytokines.
The adapted immune system is the second line of defence against N. albida. It consists of lymphocytes, such as B cells and T cells, that can recognize and eliminate specific antigens of N. albida. The adaptive immune system also generates antibodies that bind to and neutralize N. albida.
The most critical host defense against N. albida is cellular immunity, which involves activating T cells and macrophages that can phagocytose and kill N. albida. Cellular immunity is impaired in patients with HIV, leukemia, or lymphoma, which makes them more susceptible to N. albida infection.
Humoral immunity, which entails antibody production by B cells, is less effective against N. albida because this fungus has several virulence factors that can evade or inhibit the humoral response.
Clinical manifestations
The clinical manifestations of N. albida infection differ based on the infection’s location and severity. A few instances include:
Keratitis: inflammation of the cornea, which may cause redness, discomfort, impaired vision, and light sensitivity.
Pneumonia: inflammation of the lungs, which may cause fever, cough, dyspnea, and pain in the chest.
Encephalitis: brain inflammation, which may cause headache, confusion, seizures, and altered mental status.
Cutaneous cryptococcosis: skin lesions that may appear as nodules, ulcers, or abscesses.
Disseminated cryptococcosis: widespread infection that may affect multiple organs, such as the central nervous system, lungs, liver, spleen, and bones.
Diagnosis
The diagnosis of Naganishia albida is based on isolating and identifying the fungus from clinical specimens, such as blood, cerebrospinal fluid, sputum, or skin biopsy. The identification can be done by conventional methods, such as culture and microscopy, or by molecular methods, such as MALDI-TOF mass spectrometry or DNA sequencing.
Some of the characteristics of N. albida that can help in the diagnosis are:
It produces cream-coloured, smooth, mucoid, yeast-like colonies on Sabouraud dextrose agar.
It has globose to ovoid budding yeast-like cells, 3.5-8.8 x 5.5-10.2 μm, that can be seen with India ink preparation.
It has variable growth at 37°C and is usually phenol oxidase-negative and capsular polysaccharide-positive.
It is less sensitive to human serum than other Cryptococcus species.
Control
The prevention of N. albida infection may involve the following measures:
Avoid exposure to potential sources of N. albida, such as soil, plants, animals, or water that may be contaminated with the fungus.
Wearing protective equipment, such as masks, gloves, goggles, or clothing, when handling or working with materials containing N. albida.
Practicing good hygiene, such as washing hands, cleaning wounds, and disinfecting surfaces and instruments that may encounter N. albida.
Seeking medical attention if symptoms of N. albida infection occur, such as fever, cough, shortness of breath, chest pain, headache, confusion, seizures, altered mental status, skin lesions, or eye inflammation.
Taking antifungal drugs as a doctor prescribes if diagnosed with N. albida infection. Some antifungal drugs that have been used to treat N. albida infection are amphotericin B, itraconazole, naftifine, fluconazole, and voriconazole. The duration of treatment may range from several weeks to several months.
The epidemiology of Naganishia albida is the study of the distribution and determinants of this yeast-like fungus in different populations and environments. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some facts about the epidemiology of N. albida:
Based on phylogenetic analysis, N. albida was formerly known as Cryptococcus albidus but was reclassified in 2015.
N. albida is usually found on natural substrates, such as soil and plants, and rarely causes human infections. However, some cases of infection have been reported from various countries, such as Japan, Portugal, Iran, India, Brazil, and the USA.
The most common risk factor for N. albida infection is impaired cellular immunity, such as in patients with HIV, leukemia, or lymphoma. Other risk factors may include diabetes mellitus, chronic renal failure, organ transplantation, corticosteroid therapy, and trauma.
The clinical manifestations of N. albida infection differ based on the location and severity of the infection. Some examples are keratitis, pneumonia, encephalitis, cutaneous cryptococcosis, and disseminated cryptococcosis.
The treatment of N. albida infection depends on the severity and location of the infection. Antifungal drugs are the mainstay of therapy, but their efficacy may vary depending on the strain and the patient’s immune status. Some antifungal drugs that have been used to treat N. albida infection are amphotericin B, itraconazole, naftifine, fluconazole, and voriconazole. The course of treatment could last anything from a few weeks to several months. In some cases, surgical intervention may be required to remove infected tissue or drain abscesses.
Classification and Structure
Kingdom: Fungi
Division: Basidiomycota
Class: Tremellomycetes
Order: Filobasidiales
Family: Filobasidiaceae
Genus: Naganishia
Species:N. albida
The structure of Naganishia albida can be described in five points as follows:
Naganishia albida is a yeast-like fungus that belongs to the family Filobasidiaceae. It is currently only known for its yeast state.
Naganishia albida produces cream to pale pink colonies on culture media, primarily smooth and mucoid but sometimes rough and wrinkled.
Naganishia albida has globose to ovoid budding yeast-like cells, which measure 3.5-8.8 x 5.5-10.2 μm in size.
Naganishia albida has a polysaccharide capsule surrounding the cell wall and can be seen with India ink staining12. The capsule has four antigenic types: A1, A2, B1, and B2.
Naganishia albida does not form pseudohyphae or true hyphae; its sexual reproduction is unknown. It can assimilate various carbon and nitrogen sources and produce urease.
Antigenic Types
Different strains of N. albida can be distinguished by various criteria, such as phenol oxidase activity, capsular polysaccharide production, and DNA sequence analysis. Some of the strains that have been isolated and identified are:
N. albida var. albidus: This strain type of N. albida was initially isolated from the air in Japan. It is phenol oxidase-negative and capsular polysaccharide-positive.
N. albida var. kuetzingii: This strain was isolated from a grasshopper in Portugal. It is phenol oxidase-positive and capsular polysaccharide-negative.
N. albida var. ovalis: This strain was isolated from a tubercular lung. It is phenol oxidase-negative and capsular polysaccharide-negative.
N. albida FJI-L2-BK-P3: This strain was isolated from a dry moss in Portugal5. DNA sequence analysis shows it belongs to a different clade than the other strains.
Pathogenesis
The pathogenesis of Naganishia albida is the process by which this yeast-like fungus causes disease in humans or animals. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some aspects of the pathogenesis of N. albida:
N. albida is usually found on natural substrates, such as soil and plants, and rarely causes human infections.
Inhaling airborne particles is the most typical method of infecting spores or cells of N. albida, which can reach the lungs and cause pneumonia. Other routes of infection may include direct injection of the fungus into the skin, eyes, or other mucous membranes or ingesting contaminated food or water.
The most common risk factor for N. albida infection is impaired cellular immunity, such as in patients with HIV, leukemia, or lymphoma. Other risk factors may include diabetes mellitus, chronic renal failure, organ transplantation, corticosteroid therapy, and trauma.
N. albida has several virulence factors that enable it to evade the host immune system and cause tissue damage.
Host Defenses
The host defenses of Naganishia albida are the mechanisms by which the human or animal immune system protects itself from this yeast-like fungus. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some aspects of the host defenses of N. albida:
The innate immune system is the first defense against N. albida. It consists of physical barriers, such as the skin and mucous membranes, and cellular and molecular components, such as macrophages, neutrophils, natural killer cells, complement, and cytokines.
The adapted immune system is the second line of defence against N. albida. It consists of lymphocytes, such as B cells and T cells, that can recognize and eliminate specific antigens of N. albida. The adaptive immune system also generates antibodies that bind to and neutralize N. albida.
The most critical host defense against N. albida is cellular immunity, which involves activating T cells and macrophages that can phagocytose and kill N. albida. Cellular immunity is impaired in patients with HIV, leukemia, or lymphoma, which makes them more susceptible to N. albida infection.
Humoral immunity, which entails antibody production by B cells, is less effective against N. albida because this fungus has several virulence factors that can evade or inhibit the humoral response.
Clinical manifestations
The clinical manifestations of N. albida infection differ based on the infection’s location and severity. A few instances include:
Keratitis: inflammation of the cornea, which may cause redness, discomfort, impaired vision, and light sensitivity.
Pneumonia: inflammation of the lungs, which may cause fever, cough, dyspnea, and pain in the chest.
Encephalitis: brain inflammation, which may cause headache, confusion, seizures, and altered mental status.
Cutaneous cryptococcosis: skin lesions that may appear as nodules, ulcers, or abscesses.
Disseminated cryptococcosis: widespread infection that may affect multiple organs, such as the central nervous system, lungs, liver, spleen, and bones.
Diagnosis
The diagnosis of Naganishia albida is based on isolating and identifying the fungus from clinical specimens, such as blood, cerebrospinal fluid, sputum, or skin biopsy. The identification can be done by conventional methods, such as culture and microscopy, or by molecular methods, such as MALDI-TOF mass spectrometry or DNA sequencing.
Some of the characteristics of N. albida that can help in the diagnosis are:
It produces cream-coloured, smooth, mucoid, yeast-like colonies on Sabouraud dextrose agar.
It has globose to ovoid budding yeast-like cells, 3.5-8.8 x 5.5-10.2 μm, that can be seen with India ink preparation.
It has variable growth at 37°C and is usually phenol oxidase-negative and capsular polysaccharide-positive.
It is less sensitive to human serum than other Cryptococcus species.
Control
The prevention of N. albida infection may involve the following measures:
Avoid exposure to potential sources of N. albida, such as soil, plants, animals, or water that may be contaminated with the fungus.
Wearing protective equipment, such as masks, gloves, goggles, or clothing, when handling or working with materials containing N. albida.
Practicing good hygiene, such as washing hands, cleaning wounds, and disinfecting surfaces and instruments that may encounter N. albida.
Seeking medical attention if symptoms of N. albida infection occur, such as fever, cough, shortness of breath, chest pain, headache, confusion, seizures, altered mental status, skin lesions, or eye inflammation.
Taking antifungal drugs as a doctor prescribes if diagnosed with N. albida infection. Some antifungal drugs that have been used to treat N. albida infection are amphotericin B, itraconazole, naftifine, fluconazole, and voriconazole. The duration of treatment may range from several weeks to several months.
The epidemiology of Naganishia albida is the study of the distribution and determinants of this yeast-like fungus in different populations and environments. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some facts about the epidemiology of N. albida:
Based on phylogenetic analysis, N. albida was formerly known as Cryptococcus albidus but was reclassified in 2015.
N. albida is usually found on natural substrates, such as soil and plants, and rarely causes human infections. However, some cases of infection have been reported from various countries, such as Japan, Portugal, Iran, India, Brazil, and the USA.
The most common risk factor for N. albida infection is impaired cellular immunity, such as in patients with HIV, leukemia, or lymphoma. Other risk factors may include diabetes mellitus, chronic renal failure, organ transplantation, corticosteroid therapy, and trauma.
The clinical manifestations of N. albida infection differ based on the location and severity of the infection. Some examples are keratitis, pneumonia, encephalitis, cutaneous cryptococcosis, and disseminated cryptococcosis.
The treatment of N. albida infection depends on the severity and location of the infection. Antifungal drugs are the mainstay of therapy, but their efficacy may vary depending on the strain and the patient’s immune status. Some antifungal drugs that have been used to treat N. albida infection are amphotericin B, itraconazole, naftifine, fluconazole, and voriconazole. The course of treatment could last anything from a few weeks to several months. In some cases, surgical intervention may be required to remove infected tissue or drain abscesses.
Classification and Structure
Kingdom: Fungi
Division: Basidiomycota
Class: Tremellomycetes
Order: Filobasidiales
Family: Filobasidiaceae
Genus: Naganishia
Species:N. albida
The structure of Naganishia albida can be described in five points as follows:
Naganishia albida is a yeast-like fungus that belongs to the family Filobasidiaceae. It is currently only known for its yeast state.
Naganishia albida produces cream to pale pink colonies on culture media, primarily smooth and mucoid but sometimes rough and wrinkled.
Naganishia albida has globose to ovoid budding yeast-like cells, which measure 3.5-8.8 x 5.5-10.2 μm in size.
Naganishia albida has a polysaccharide capsule surrounding the cell wall and can be seen with India ink staining12. The capsule has four antigenic types: A1, A2, B1, and B2.
Naganishia albida does not form pseudohyphae or true hyphae; its sexual reproduction is unknown. It can assimilate various carbon and nitrogen sources and produce urease.
Antigenic Types
Different strains of N. albida can be distinguished by various criteria, such as phenol oxidase activity, capsular polysaccharide production, and DNA sequence analysis. Some of the strains that have been isolated and identified are:
N. albida var. albidus: This strain type of N. albida was initially isolated from the air in Japan. It is phenol oxidase-negative and capsular polysaccharide-positive.
N. albida var. kuetzingii: This strain was isolated from a grasshopper in Portugal. It is phenol oxidase-positive and capsular polysaccharide-negative.
N. albida var. ovalis: This strain was isolated from a tubercular lung. It is phenol oxidase-negative and capsular polysaccharide-negative.
N. albida FJI-L2-BK-P3: This strain was isolated from a dry moss in Portugal5. DNA sequence analysis shows it belongs to a different clade than the other strains.
Pathogenesis
The pathogenesis of Naganishia albida is the process by which this yeast-like fungus causes disease in humans or animals. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some aspects of the pathogenesis of N. albida:
N. albida is usually found on natural substrates, such as soil and plants, and rarely causes human infections.
Inhaling airborne particles is the most typical method of infecting spores or cells of N. albida, which can reach the lungs and cause pneumonia. Other routes of infection may include direct injection of the fungus into the skin, eyes, or other mucous membranes or ingesting contaminated food or water.
The most common risk factor for N. albida infection is impaired cellular immunity, such as in patients with HIV, leukemia, or lymphoma. Other risk factors may include diabetes mellitus, chronic renal failure, organ transplantation, corticosteroid therapy, and trauma.
N. albida has several virulence factors that enable it to evade the host immune system and cause tissue damage.
Host Defenses
The host defenses of Naganishia albida are the mechanisms by which the human or animal immune system protects itself from this yeast-like fungus. N. albida is a rare human pathogen that can cause superficial and systemic infections, especially in immunocompromised patients. Here are some aspects of the host defenses of N. albida:
The innate immune system is the first defense against N. albida. It consists of physical barriers, such as the skin and mucous membranes, and cellular and molecular components, such as macrophages, neutrophils, natural killer cells, complement, and cytokines.
The adapted immune system is the second line of defence against N. albida. It consists of lymphocytes, such as B cells and T cells, that can recognize and eliminate specific antigens of N. albida. The adaptive immune system also generates antibodies that bind to and neutralize N. albida.
The most critical host defense against N. albida is cellular immunity, which involves activating T cells and macrophages that can phagocytose and kill N. albida. Cellular immunity is impaired in patients with HIV, leukemia, or lymphoma, which makes them more susceptible to N. albida infection.
Humoral immunity, which entails antibody production by B cells, is less effective against N. albida because this fungus has several virulence factors that can evade or inhibit the humoral response.
Clinical manifestations
The clinical manifestations of N. albida infection differ based on the infection’s location and severity. A few instances include:
Keratitis: inflammation of the cornea, which may cause redness, discomfort, impaired vision, and light sensitivity.
Pneumonia: inflammation of the lungs, which may cause fever, cough, dyspnea, and pain in the chest.
Encephalitis: brain inflammation, which may cause headache, confusion, seizures, and altered mental status.
Cutaneous cryptococcosis: skin lesions that may appear as nodules, ulcers, or abscesses.
Disseminated cryptococcosis: widespread infection that may affect multiple organs, such as the central nervous system, lungs, liver, spleen, and bones.
Diagnosis
The diagnosis of Naganishia albida is based on isolating and identifying the fungus from clinical specimens, such as blood, cerebrospinal fluid, sputum, or skin biopsy. The identification can be done by conventional methods, such as culture and microscopy, or by molecular methods, such as MALDI-TOF mass spectrometry or DNA sequencing.
Some of the characteristics of N. albida that can help in the diagnosis are:
It produces cream-coloured, smooth, mucoid, yeast-like colonies on Sabouraud dextrose agar.
It has globose to ovoid budding yeast-like cells, 3.5-8.8 x 5.5-10.2 μm, that can be seen with India ink preparation.
It has variable growth at 37°C and is usually phenol oxidase-negative and capsular polysaccharide-positive.
It is less sensitive to human serum than other Cryptococcus species.
Control
The prevention of N. albida infection may involve the following measures:
Avoid exposure to potential sources of N. albida, such as soil, plants, animals, or water that may be contaminated with the fungus.
Wearing protective equipment, such as masks, gloves, goggles, or clothing, when handling or working with materials containing N. albida.
Practicing good hygiene, such as washing hands, cleaning wounds, and disinfecting surfaces and instruments that may encounter N. albida.
Seeking medical attention if symptoms of N. albida infection occur, such as fever, cough, shortness of breath, chest pain, headache, confusion, seizures, altered mental status, skin lesions, or eye inflammation.
Taking antifungal drugs as a doctor prescribes if diagnosed with N. albida infection. Some antifungal drugs that have been used to treat N. albida infection are amphotericin B, itraconazole, naftifine, fluconazole, and voriconazole. The duration of treatment may range from several weeks to several months.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
